Geographic variation in sodium-glucose cotransporter 2 inhibitor and glucagon-like peptide-1 receptor agonist use in people with type 2 diabetes in New South Wales, Australia.
Juliana de Oliveira CostaJialing LinTamara Y MilderJerry R GreenfieldRichard Osborne DaySophie Lena StockerBrendon L NeuenAlys HavardSallie-Anne PearsonMichael O FalsterPublished in: Diabetes, obesity & metabolism (2024)
The prevalence of SGLT2i and GLP-1RA use varied by geography, probably reflecting a combination of system- and prescriber-level factors. Socio-economic variation in GLP-1RA use was overshadowed by localized patterns of prescribing. Continued monitoring of variation can help shape interventions to optimize use among people who would benefit the most.